Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Gilead Sciences
Gilead Sciences
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
Institut Cancerologie de l'Ouest
Eli Lilly and Company
University of Miami
Stanford University
NYU Langone Health
Sanofi
Odense University Hospital
Roswell Park Cancer Institute
Ottawa Hospital Research Institute
Samsung Medical Center
Roswell Park Cancer Institute
Sanofi
Massachusetts General Hospital